论文部分内容阅读
目的:本次研究通过对比分析的方法综合评价美多芭对于帕金森患者的临床治疗治疗效果及其药物安全性。方法:本次研究所需的研究对象从本院进行选取,随机从2012年9月至2014年12月间在院接受治疗的帕金森病患中抽取59例,按照随机双盲法将本组患者分成研究组和治疗组,前者30例,予以美多芭治疗,后者29例,采用多巴胺受体激动剂药物治疗,观察分析患者经过各自治疗方案治疗后的日常生活能力以及运动功能的改善情况,同时对比分析两组研究对象药物不良反应的发生情况。结果:通过治疗后所有患者的日常生活能力以及运动功能发生明显改善,并且研究组改善幅度显著优于对照组,就药物不良反应发生情况而言,两组无显著性差异,通过统计学处理分析差异存在显著性(P<0.05),但研究组发生率略低于对照组。结论:就帕金森病患临床治疗问题而言,多巴胺受体激动剂效果值得肯定,但研究发现美多芭治疗效果更佳,其能够明显改善患者的日常生活能力和运动功能,有效提高临床治疗效率,同时还不会增加不良的药物反应,值得推广。
OBJECTIVE: In this study, we evaluated the clinical effects of metoprolol in Parkinson’s disease and its drug safety by comparative analysis. METHODS: The subjects required for this study were selected from our hospital and randomized 59 patients with Parkinson’s disease who were hospitalized from September 2012 to December 2014, randomized to double-blind Patients were divided into study group and treatment group, the former 30 patients were treated with metoprolol, the latter 29 patients with dopamine agonist drug therapy, observation and analysis of patients after treatment of their daily living ability and improvement of motor function Situation, at the same time comparative analysis of two groups of subjects adverse drug reactions occurred. Results: After treatment, the daily living ability and motor function of all patients significantly improved, and the improvement rate of the study group was significantly better than that of the control group. There was no significant difference between the two groups in the incidence of adverse drug reactions. By statistical analysis The difference was significant (P <0.05), but the study group was slightly lower than the control group. Conclusion: The effect of dopamine receptor agonists is worthy of recognition for the clinical treatment of Parkinson’s disease. However, the study found that metoprolol treatment is more effective, which can significantly improve patients’ daily living ability and motor function, and effectively improve clinical treatment Efficiency, while not increasing adverse drug reactions, is worth promoting.